Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the ...

BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $26 from $30 and keeps a Buy rating on the shares. While ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

HUTCHMED (China) is not owned by hedge funds. Hutchison Whampoa (China) Limited is currently the largest shareholder, with 39% of shares outstanding. In comparison, the second and third largest ...

Hutchmed has agreed to divest its share of a Chinese joint venture company through a pair of deals that will give it a cash injection of around $608 million. The deal will see Hutchmed sell its 45 ...

Hutchmed to divest its 45% equity interest in SHPL to GP Health Service Capital & Shanghai Pharma for approx. US$ 608 million: Hong Kong, Shanghai Friday, January 3, 2025, 13:00 H ...

(Sharecast News) - Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment and a substantial divestment aimed at bolstering ...

HUTCHMED (China) has agreed to sell a 45% equity interest in the non-core, non-consolidated joint venture (JV) Shanghai ...